{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:17:36Z","timestamp":1784233056398,"version":"3.55.0"},"reference-count":22,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.25070","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:10:20Z","timestamp":1772230220000},"page":"80-84","source":"Crossref","is-referenced-by-count":2,"title":["CD19 CAR T-cell therapy for relapsed\/refractory diffuse large B-cell lymphoma in a nonagenarian patient"],"prefix":"10.3960","volume":"66","author":[{"given":"Jotaro","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kaji","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"},{"name":"Department of Transfusion and Cellular Therapy, Toranomon Hospital, Tokyo, Japan,"},{"name":"Center for Cellular Therapy, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kuno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otoya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki , Kanagawa, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki , Kanagawa, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Taya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"},{"name":"Department of Transfusion and Cellular Therapy, Toranomon Hospital, Tokyo, Japan,"},{"name":"Center for Cellular Therapy, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"},{"name":"Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan,"},{"name":"Okinaka Memorial Institute for Medical Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"},{"name":"Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Asano-Mori","sequence":"additional","affiliation":[{"name":"Department of Transfusion and Cellular Therapy, Toranomon Hospital, Tokyo, Japan,"},{"name":"Center for Cellular Therapy, Toranomon Hospital, Tokyo, Japan,"},{"name":"Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki , Kanagawa, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"},{"name":"Okinaka Memorial Institute for Medical Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toranomon Hospital, Tokyo, Japan,"},{"name":"Center for Cellular Therapy, Toranomon Hospital, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Neelapu SS, Locke FL, Bartlett NL <i>et al.<\/i> Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377: 2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Abramson JS, Palomba ML, Gordon LI <i>et al.<\/i> Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396: 839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ram R, Grisariu S, Shargian-Alon L <i>et al.<\/i> Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. Haematologica. 2022; 107: 1111-1118.","DOI":"10.3324\/haematol.2021.278288"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Chihara D, Liao L, Tkacz J <i>et al.<\/i> Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2023; 142: 1047-1055.","DOI":"10.1182\/blood.2023020197"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Sehgal A, Hoda D, Riedell PA <i>et al.<\/i> Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022; 23: 1066-1077.","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Merli F, Luminari S, Tucci A <i>et al.<\/i> Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. J Clin Oncol. 2021; 39: 1214-1222.","DOI":"10.1200\/JCO.20.02465"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tanaka T, Sakai R, Choi I <i>et al.<\/i> Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma. Sci Rep. 2022; 12: 3124.","DOI":"10.1038\/s41598-022-07164-w"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Bouillanne O, Morineau G, Dupont C <i>et al.<\/i> Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005; 82: 777-783.","DOI":"10.1093\/ajcn\/82.4.777"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Bellera CA, Rainfray M, Mathoulin-P\u00e9lissier S <i>et al.<\/i> Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012; 23: 2166-2172.","DOI":"10.1093\/annonc\/mdr587"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Kharfan-Dabaja MA, Mohty R, Easwar N <i>et al.<\/i> Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone Marrow Transplant. 2025; 60: 632-639.","DOI":"10.1038\/s41409-025-02541-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Bail\u00e9n R, Iacoboni G, Delgado J <i>et al.<\/i> Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC\/GELTAMO. Transplant Cell Ther. 2024; 30: 988.e1-988.e11","DOI":"10.1016\/j.jtct.2024.06.022"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Tun AM, Patel RD, St-Pierre F <i>et al.<\/i> Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study. Am J Hematol. 2024; 99: 1712-1720","DOI":"10.1002\/ajh.27381"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Yates SJ, Cursio JF, Artz A <i>et al.<\/i> Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024; 8: 3785-3797.","DOI":"10.1182\/bloodadvances.2024012727"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Greenbaum U, Hashmi H, Elsawy M <i>et al.<\/i> New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Adv. 2026; 10: 217-227.","DOI":"10.1182\/bloodadvances.2024015599"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Looka A, Qualls DA, Matthews D <i>et al.<\/i> A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma. Blood Adv. 2025; 9: 455-462.","DOI":"10.1182\/bloodadvances.2024012992"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Bachy E, Gouill SL, Blasi RD <i>et al.<\/i> A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022; 28: 2145-2154.","DOI":"10.1038\/s41591-022-01969-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Philippis CD, Mannina D, Giordano L <i>et al.<\/i> Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023; 29: 429.e1-429.e6.","DOI":"10.1016\/j.jtct.2023.03.019"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Gardner RA, Ceppi F, Rivers J <i>et al.<\/i> Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019; 134: 2149-2158.","DOI":"10.1182\/blood.2019001463"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Crochet G, Iacoboni G, Couturier A <i>et al.<\/i> Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 2024; 144: 334-338.","DOI":"10.1182\/blood.2024024526"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Philipp N, Kazerani M, Nicholls A <i>et al.<\/i> T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022; 140: 1104-1118.","DOI":"10.1182\/blood.2022015956"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Mishra A, Maiti R, Mohan P, Gupta P. Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions. Eur J Haematol. 2024; 112: 211-222.","DOI":"10.1111\/ejh.14101"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/1\/66_25070\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:31:14Z","timestamp":1775277074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/1\/66_25070\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25070","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"25070"}}